McKinney’s StatLab Medical Products, a developer and manufacturer of anatomic pathology diagnostic supplies, has acquired BBC Biochemical, a chemical supply company. The investment shows StatLab’s commitment to giving anatomic pathology labs access to the highest quality products, and represents its growth as a company.
StatLab solutions empower anatomic pathologists, who study the effects of disease on organs as a whole and microscopically, to detect cancer earlier and improve outcomes. CEO Dan Eckert said the acquisition further positions the company as a leading manufacturer of cancer diagnostics for labs and other companies in the U.S. and globally.
“Together, with increased manufacturing capabilities and capacity, StatLab now offers unparalleled access to formalin prefills throughout the United States, and has expanded the reach of our international OEM business,” he said.
BBC Biochemical, based in Mount Vernon, Washington, provides various products and services to laboratories. It was founded around three decades ago by a pathologist who wanted to improve the quality of anatomic pathology supplies. StatLab said on LinkedIn that BBC Biochemical shares its “passionate commitment to providing quality products and services to customers.”
“This partnership with StatLab brings even greater product access, faster delivery, and product support to our customers,” BBC Biochemical President Adrian Biesecker said.
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.
R E A D N E X T
-
The EdTech marketplace and PaaS startup will expand its HQ with a grant from the McKinney Economic Development Corporation's (MEDC) Innovation Fund. The startup connects learning resource buyers and sellers in 7,000 languages and dialects. The woman-owned and minority-led company says it's "empowering micro-entrepreneurs to reach their customers globally."
-
The investment was led by Advantech Capital, a PE fund based in China that focuses on TMT, pharmaceuticals, and healthcare. This combined with the support from the Cancer Prevention and Research Institute of Texas (CPRIT), which granted OncoNano $9.97 million last year, will support Phase 3 clinical trials for the biotech's technology that can diagnose and treat cancer with high specificity.
-
Southlake-based OncoNano Medicine uses pH-sensitive nanoparticle technology to "light up" cancer for real-time surgical imaging. The multi-year collaboration will seek to uncover new cancer therapies that can benefit from OncoNano's technology. OncoNano raised $50 million in Series B funding in June.
-
The Cancer Prevention and Research Institute of Texas awarded a $3.9 million grant to The University of North Texas Health Science Center (HSC) in Fort Worth to expand a program that aims to create more diversity in the medical and biomedical sciences fields.
-
The Cancer Prevention and Research Institute of Texas (CPRIT) will convert previous grant awards to an equity investment. OncoNano uses pH as a biomarker to detect metastatic cancer. The technology "lights up" a tumor in imaging during real-time surgery.
